1. Dattilo PB. Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report. Cases J. 2009;2:9295-9298.
  2. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057-1062.
  3. Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid
    polyneuropathy (TTR-FAP). Neurology. 2007;69:693-698.
  4. Pareyson D. Diagnosis of hereditary neuropathies in adult patients. J Neurol. 2003;250:148-160.
  5. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411-423.
  6. Rudolph T, Kurz MW, Farbu E. Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history. Clin Med Res.
  7. Shirota Y, Iwata A, Ishiura H, et al. A case of atypical amyloid polyneuropathy with predominant upper-limb involvement with diagnosis unexpectedly found at lung operation. Intern Med. 2010;49:1627-1631.
  8. Zeldenrust SR. ATTR: diagnosis, prognosis, and treatment. In: Gertz MA, Rajkumar V, eds. Amyloidosis, Contemporary Hematology. 2010:191-204.
  9. Sekijima Y, Yoshida K, Tokuda T, Ikeda S. Familial transthyretin amyloidosis. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle WA: University of Washington, 1993-2009.
  10. Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274:1637-1650.
  11. Coutinho P, da Silva AM, Lima JL, Barbosa AR. Forty years of experience with type 1 amyloid neuropathy: review of 483 cases.
    In: Glenner GG, e Costa PP, de Freitas AF, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88-98.
  12. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol.
  13. Holmgren G, Costa PMP, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994;31:351-354.
  14. Kato-Motozaki Y, Ono K, Shima K, et al. Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus. J Neurol Sci. 2008;270:133-140.
  15. Saporta MAC, Zaros C, Cruz MW, et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type 1) in Brazilian families.
    Eur J Neurol
    . 2009;16:337-341.
  16. Snanoudj R, Durrbach A, Gauthier E, et al. Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol Dial Transplant. 2004;19:1779-1785.
  17. Suhr OB, Svendsen IH, Andersson R, et al. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med. 2003;254:225-235.
  18. Jonsèn E, Athlin E, Suhr O. Familial amyloidotic patients' experience of the disease and of liver transplantation. J Adv Nurs.
  19. Graceffa A, Russo M, Luca-Vita G, et al. Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscul Disord. 2009;19:44-48.
  20. Lindgren M, Sörgjerd K, Hammarström P. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. Biophys J. 2005;88:4200-4212.
  21. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology.